Biotech | September 16, 2025
Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
